文献速递妇科肿瘤

PM01183对比拓扑替康治疗铂耐药/难治性晚期卵巢癌的II期随机研究

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.
PubMed 文献 · Ann Oncol · 2017-01-01

这项II期随机研究纳入铂耐药/难治性卵巢癌患者,第一阶段22例确认PM01183单药7.0 mg每3周方案活性,第二阶段59例随机对照拓扑替康。PM01183组52例客观缓解率23%(95%CI 13%-37%),铂耐药患者33例中客观缓解率30%(95%CI 16%-49%),拓扑替康组29例无缓解。结论认为PM01183在铂耐药/难治性卵巢癌中有活性、值得进一步开发,安全性提示应按体表面积调整剂量(mg/m2)。

要点

  • PM01183单药治疗52例铂耐药/难治性卵巢癌,客观缓解率23%(95%CI 13%-37%)。
  • 33例铂耐药患者中客观缓解率30%(95%CI 16%-49%),12例确认缓解中10例来自该组。
  • 第二阶段29例拓扑替康治疗患者中未观察到缓解。

核心结论

  • PM01183是铂耐药/难治性卵巢癌中有活性的药物,值得进一步开发;活性最高见于铂耐药疾病;安全性特征提示剂量应按体表面积调整(mg/m2)。

研究设计与样本

  • 两阶段、对照、随机(第二阶段)、多中心II期研究,纳入铂耐药/难治性卵巢癌患者。
  • 主要终点为按RECIST和/或GCIG标准的客观缓解率。
  • 探索性第一阶段22例确认PM01183单药7.0 mg固定剂量每3周方案的活性。
  • 第二阶段59例随机对照拓扑替康,给药为第1-5天每3周或每周(每4周)方案。

主要发现

  • PM01183组52例客观缓解率为23%(95%CI 13%-37%)。
  • 缓解中位持续时间为4.6个月(95%CI 2.5-6.9个月),23%(95%CI 0%-51%)的缓解持续6个月或以上。
  • 12例确认缓解中10例来自33例铂耐药患者,该组客观缓解率为30%(95%CI 16%-49%)。
  • 第二阶段29例拓扑替康治疗患者中未发现缓解。
  • 全部PM01183治疗患者中位无进展生存期为4.0个月(95%CI 2.7-5.6个月),铂耐药患者为5.0个月(95%CI 2.7-6.9个月)。

临床怎么用

  • 原文结论认为PM01183是铂耐药/难治性卵巢癌中有活性的药物并值得进一步开发,安全性特征提示剂量应按体表面积调整(mg/m2)。

局限性

  • 原文结论指出PM01183值得进一步开发,未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PM01183 is a new compound that blocks active transcription, produces DNA breaks and apoptosis, and affects the inflammatory microenvironment. PM01183 showed strong antitumor activity in preclinical models of cisplatin-resistant epithelial ovarian cancer. PATIENTS AND METHODS: Patients with platinum-resistant/refractory ovarian cancer were included in a two-stage, controlled, randomized (in a second stage), multicenter, phase II study. Primary endpoint was overall response rate (ORR) by RECIST and/or GCIG criteria. The exploratory first stage (n = 22) confirmed the activity of PM01183 as a single agent at 7.0 mg flat dose every 3 weeks (q3wk). The second stage (n = 59) was randomized and controlled with topotecan on days 1-5 q3wk or weekly (every 4 weeks, q4wk). RESULTS: ORR was 23% (95% CI, 13%-37%) for 52 PM01183-treated patients. Median duration of response was 4.6 months (95% CI, 2.5-6.9 months), and 23% (95% CI, 0%-51%) of responses lasted 6 months or more. Ten of the 12 confirmed responses were reported for 33 patients with platinum-resistant disease [ORR = 30% (95% CI, 16%-49%)]; for the 29 patients treated with topotecan in the second stage, no responses were found. Median PFS for all PM01183-treated patients was 4.0 months (95% CI, 2.7-5.6 months), and 5.0 months (95% CI, 2.7-6.9 months) for patients with platinum-resistant disease. Grade 3/4 neutropenia in 85% of patients; febrile neutropenia in 21% and fatigue (grade 3 in 35%) were the principal safety findings for PM01183. CONCLUSION: PM01183 is an active drug in platinum-resistant/refractory ovarian cancer and warrants further development. The highest activity was observed in platinum-resistant disease. Its safety profile indicates the dose should be adjusted to body surface area (mg/m2). TRIAL CODE: EudraCT 2011-002172-16.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Poveda A, Del Campo JM, Ray-Coquard I, et al. Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer. Ann Oncol. 2017. PMID: 28368437. doi:10.1093/annonc/mdx111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。